Page added to clipboard.

The ‘Long’ and Short of it: Dr. Goldstein’s Glioblastoma Research


3242 Hannah Goldstein-005web
Third-year neurosurgery resident Dr. Hannah Goldstein

Congratulations to third-year resident Dr. Hannah Goldstein. She received a prestigious research fellowship from the National Institute of Neurological Disorders and Stroke to study a gene called PTEN-Long.

NINDS, which is part of the National Institutes of Health, provided funding for Dr. Goldstein’s research into new brain tumor treatment.

Dr. Goldstein conducted her research with mentor Dr. Jeffrey Bruce in the Bartoli Brain Tumor Lab. Dr. Goldstein’s research focused on PTEN-Long, a naturally occurring tumor suppressing gene. The gene could help fight a deadly brain tumor called glioblastoma.

The approach is a new one. As Dr. Goldstein explains, “PTEN-Long is an endogenous tumor suppressor protein.” That means it occurs naturally in the body. For unknown reasons, it is deactivated in cases of glioblastoma. “Rather than introducing a protein designed to inhibit a [cancer gene],” says Dr. Goldstein, PTEN-Long “gives tumor-suppressing function back to the cell.”

The possibility is exciting. This research could lead to a new tool in the fight against glioblastoma, a notoriously difficult cancer to treat. The tumor grows aggressively, and it can almost never be fully removed with surgery.

Dr. Goldstein presented her results at the NINDS research workshop in Bethesda, MD, in June 2015. The title of her poster was “PTEN-Long: The Use of a Tumor Suppressor in the Treatment of Glioblastoma Multiforme.” (For a full list of authors, see below.)

The results of Dr. Goldstein’s research are promising. But there’s more work to be done before the approach is ready for use. Coming research will focus on the best ways to deliver PTEN-Long to the exact places where it can do the most good.

Dr. Jeffrey Bruce
Mentor Dr. Jeffrey Bruce, Director of Bartoli Brain Tumor Laboratory

If PTEN-Long becomes a treatment, it will not only provide a new method for fighting glioblastoma, it will also help researchers seek other potential glioma treatments. “Using naturally occurring tumor suppressors as part of the treatment paradigm for glioblastoma has far-reaching implications,” says Dr. Goldstein.

Learn more about Dr. Hannah Goldstein on her bio page here.

Learn more about Dr. Jeffrey Bruce on his bio page here.

Full list of authors: Hannah Goldstein, MD; Matei Banu, MD; Benjamin Hopkins, PhD; Ramon Parsons, MD, PhD; Peter Canoll, MD, PhDJeffrey Bruce, MD

patient journey

Use this button to save pages to your clipboard for future use.

OK. Got it.